Conestoga Capital Advisors, an asset administration firm, launched its second-quarter 2025 investor letter. A duplicate of the letter may be downloaded here. The second quarter started with a traditionally poor begin however gained momentum later as tariff fears subsided and market volatility dropped precipitously. Conestoga Mid Cap Composite returned 3.46% net-of-fees within the quarter, trailing the Russell Mid Cap Progress Index’s 18.20% return. After a robust first quarter in 2025, investor enthusiasm shifted in the direction of high-beta and AI shares following the “Liberation Day” bulletins, making a slim management group that posed challenges for the Mid Cap Technique within the second quarter. Please assessment the fund’s high 5 holdings to realize perception into their key choices for 2025.
In its second quarter 2025 investor letter, Conestoga Capital Advisors highlighted shares resembling IDEXX Laboratories, Inc. (NASDAQ:IDXX). IDEXX Laboratories, Inc. (NASDAQ:IDXX) develops, manufactures, and distributes merchandise primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets. The one-month return of IDEXX Laboratories, Inc. (NASDAQ:IDXX) was 5.38%, and its shares gained 19.58% of their worth over the past 52 weeks. On July 25, 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) inventory closed at $565.19 per share, with a market capitalization of $45.454 billion.
Conestoga Capital Advisors acknowledged the next relating to IDEXX Laboratories, Inc. (NASDAQ:IDXX) in its second quarter 2025 investor letter:
“IDEXX Laboratories, Inc. (NASDAQ:IDXX) is the business chief in offering devices (and consumables) utilized in diagnostics, detection, and data methods for veterinary, meals, and water testing functions. Earnings for the quarter have been stable and steering for high-single-digit natural income progress was maintained, regardless of weak visitors tendencies. Shares rallied off five-year low valuation and the ‘better-than-feared’ ends in the quarter.”
A veterinarian in a veterinary clinic analyzing a companion animal.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) will not be on our listing of 30 Most Popular Stocks Among Hedge Funds. As per our database, 51 hedge fund portfolios held IDEXX Laboratories, Inc. (NASDAQ:IDXX) on the finish of the primary quarter, which was 58 within the earlier quarter. Within the first quarter of 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) reported natural income progress of 5% pushed by 4.5% natural income positive factors within the CAG enterprise, 7% natural progress in water, and 4% natural progress in LPD. Whereas we acknowledge the potential of IDEXX Laboratories, Inc. (NASDAQ:IDXX) as an funding, we imagine sure AI shares supply higher upside potential and carry much less draw back threat. Should you’re searching for a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the best short-term AI stock.
